Sort
8,912 grants matching “sars cov 2”
Identification of olfactory mucosa protein fingerprints in COVID-19
$235,500Qizhi Gong · University Of California At Davis · R21 · FY2021 · AI
The Unilateral Mosaic (UMos): Novel tools to compartmentalize pathology and trace cellular interactions in mouse models of human disease
$235,500David W Gludish · Cornell University · R21 · FY2024 · OD
Unravelling the mechanisms of virus host species jump
$235,500Grant McFadden · Arizona State University-Tempe Campus · R21 · FY2021 · AI
Broad-based spike protein stalk-based vaccine platform for SARS-CoV-2 and other coronaviruses
$235,500Gary R Whittaker · Cornell University · R21 · FY2022 · AI
Quantifying the spectrum and dynamics of B-cell binding avidity in response to influenza
$235,500Steven Carl George · University Of California At Davis · R21 · FY2022 · AI
Improving the Immune Response to Nanoparticle-Based SARS-CoV-2 Vaccines
$235,500Szu-Wen Wang · University Of California-Irvine · R21 · FY2023 · AI
COVID-19 and Kidney Injury: Urinary Transcriptomics of Kidney Injury in Novel Nonhuman Primate Models of SARS-CoV-2
$235,276Minolfa C Prieto · Tulane University Of Louisiana · R21 · FY2022 · AI
Predictive Modeling & Optimal Control Framework for Model-Based Epidemic Response in Delaware
$234,918Steven J. Stanhope · University Of Delaware · P20 · FY2021 · GM
CoVPN 3004 A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Immunogenicity of a SARS-CoV-2 Spike Protein Nanoparticle Vaccine in Adults
$234,860Peter B. Gilbert · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
Using Remote Sensing Technology to Assess Parent-Infant Interactions as a Mechanism Linking COVID-related Stress and Infant Neurobehavioral Functioning
$234,822Nancy L McElwain · University Of Illinois At Urbana-Champaign · R34 · FY2021 · DA
The role of precarious work in the production of health disparities in older ages
$234,766Anjum Hajat · University Of Washington · R01 · FY2020 · AG
Regulation of B cell Responses in SLE and Other Autoimmune Diseases
$234,750Ignacio E. Sanz · Emory University · U19 · FY2024 · AI
Assessing the impact of COVID-19 interventions on human mobility and SARS-CoV-2 transmission dynamics in the United States
$234,750Sean Michael Moore · University Of Notre Dame · R21 · FY2021 · AI
Adjuvant combination for SARS-CoV-2 vaccine for the elderly
$234,750Elena Vassilieva · Emory University · R21 · FY2022 · AI
Leveraging iPSC technology to understand neuro-immune responses to SARS-CoV-2 variants
$234,750Zhexing Wen · Emory University · R21 · FY2024 · NS
Novel treatment for respiratory distress due to SARS-CoV2 infection
$234,563Kathy K Griendling · Emory University · R21 · FY2021 · AI
SARS-CoV-2 and Respiratory Virus Co-Infections Among Young Children
$234,541Annette Karena Regan · Kaiser Foundation Research Institute · R21 · FY2025 · AI
Core C: Clinical and Biostatistic Core
$234,258Srilatha Edupuganti · Emory University · U19 · FY2022 · AI
A general, virus-free platform to rapidly map SARS-CoV-2 drug resistance
$234,243Amit Choudhary · Broad Institute, Inc. · R21 · FY2021 · AI
Clinical Phenotyping and Human Core
$234,154Richard G Wunderink · Northwestern University At Chicago · P01 · FY2023 · HL
Immunoproteasome-Mediated Inflammation in Coronavirus Respiratory Infection
$234,000Jason Brice Weinberg · University Of Michigan At Ann Arbor · R21 · FY2022 · AI
MHC class II immunopeptidomics analysis of the SARS-CoV-2 proteome
$234,000Robert Lochhead · Medical College Of Wisconsin · R21 · FY2021 · AI
Dissecting SARS-CoV-2 infection in Down syndrome with congenital heart defects using patient-specific iPSCs
$234,000Mingtao Zhao · Research Inst Nationwide Children'S Hosp · R21 · FY2022 · HL
COVID-19 related inflammation as a risk factor for age-related cognitive decline and Alzheimer's Disease
$234,000Natalie Celia Tronson · University Of Michigan At Ann Arbor · R21 · FY2023 · AG
Targeting Grainyhead-Like 2 Suppresses Entry Factors of SARS-CoV-2 in Epithelial Cells of Oral Mucosa.
$234,000Wei Chen · University Of California Los Angeles · R21 · FY2022 · DE